Código QR (código de barras bidimensional)

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis

Abstract Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe AD. In Italy, lebrikizumab has been a...

Fuld beskrivelse

Na minha lista:
Principais autores: Ippazio Cosimo Antonazzo, Giampiero Girolomoni, Cataldo Patruno, Roberto Langella, Veronica Ottobrino, Lorenzo Giovanni Mantovani, Paolo Angelo Cortesi
Format: Artigo
Sprog:Inglês
Udgivet: Adis, Springer Healthcare 2025-07-01
Serier:Dermatology and Therapy
Fag:
Lebrikizumab
Budget impact analysis
Severe atopic dermatitis
Italy
Pharmacoeconomics
Online adgang:https://doi.org/10.1007/s13555-025-01475-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker